Compare OXBR & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OXBR | NXL |
|---|---|---|
| Founded | 2013 | 2010 |
| Country | Cayman Islands | United States |
| Employees | 3 | 7 |
| Industry | Property-Casualty Insurers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1M | 8.3M |
| IPO Year | N/A | N/A |
| Metric | OXBR | NXL |
|---|---|---|
| Price | $0.89 | $0.37 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | 9.8K | ★ 121.2K |
| Earning Date | 05-11-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $497.99 | $120.99 |
| Revenue Next Year | $42.14 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.76 | $0.36 |
| 52 Week High | $2.85 | $2.31 |
| Indicator | OXBR | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 42.26 | 33.69 |
| Support Level | $0.76 | N/A |
| Resistance Level | $0.95 | $0.62 |
| Average True Range (ATR) | 0.06 | 0.03 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 54.02 | 3.59 |
Oxbridge Re Holdings Ltd is a specialty property and casualty reinsurer. It provides reinsurance solutions through its subsidiary. It focuses on underwriting fully collateralized reinsurance contracts for property and casualty insurance companies in the Gulf Coast region of the United States, with an emphasis on Florida. Oxbridge specializes in underwriting medium frequency, high severity risks, where insufficient data exists to analyze effectively the risk/return profile of reinsurance contracts. The company manages its business on the basis of one operating segment, Property and Casualty Reinsurance.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.